Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Head and neck cancer comprises a group of biologically ... Most head and neck cancers are squamous cell carcinomas that originate from the epithelium of these regions.

PORTLAND, OR, UNITED STATES, March 20, 2025 /EINPresswire / -- The global skin cancer treatment market has exp ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...

Purpose: Understanding the mutational landscape of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is important in identifying biomarkers to determine which patients may benefit ...

Besides classic tobacco and alcohol risk factors, human papillomavirus (HPV) plays a role in the development of a subset of head and neck squamous cell carcinomas (HNSCCs), and notably oropharynx ...

Much less commonly, non-squamous cell oral cancers like salivary gland tumors or lymphoma may develop ... treating oral cancer and is used most commonly for early-stage oral cancers. During surgery to ...